Skip to main content
SpringerLink
Log in

Anti-Arrhythmic Drugs and Cardiac Resuscitation

  • Chapter
Book cover Cardiopulmonary Resuscitation

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 1308 Accesses

Abstract

Cardiac arrest (CA) as a result of poorly tolerated ventricular tachycardia (VT) or ventricular fibrillation (VF) is the most common cause of death in many developed countries including the United States. Even with a steady decline in morbidity and mortality from cardiovascular diseases over 30 years (1), approx 60% of the 489,171 deaths attributable to coronary artery disease (CAD) in 1990 were out-of-hospital CA. In 1998, 63% of cardiac deaths were sudden and likely arrhythmic (2). Many of these deaths could have been prevented if the responsible ventricular arrhythmia had been treated with proper resuscitative efforts. Of 350,000 men who died in 1998, 41% had out-of-hospital sudden death, and 22% had a cardiac death in the emergency department (ED) or were dead on arrival. Of 369,000 women who died that year, 52% had out-of-hospital sudden death, and 12% had a cardiac death in the ED or were dead on arrival (2).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Statistics, N.C.f.H., Advance report of final mortality statistics, 1990. Monthly Vital Statistics Report 1993; 41.

    Google Scholar 

  2. Zheng ZJ, et al. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001; 104:2158–2163.

    Article  PubMed  CAS  Google Scholar 

  3. Cobb LA. Changing incidence of out of hospital ventricular fibrillation. JAMA 2002; 288: 3008–3013.

    Article  PubMed  Google Scholar 

  4. Cummins RO, et al. Improving survival from sudden cardiac arrest: the “chain of survival” concept. A statement for health professionals from the Advanced Cardiac Life Support Subcommittee and the Emergency Cardiac Care Committee, American Heart Association. Circulation, 1991; 83:1832–1847.

    PubMed  CAS  Google Scholar 

  5. Cummins RO, et al. Survival of out-of-hospital cardiac arrest with early initiation of cardiopulmonary resuscitation. Am J Emerg Med 1985; 3:114–119.

    Article  PubMed  CAS  Google Scholar 

  6. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2000; 102(8 Suppl)11:1–291.

    Google Scholar 

  7. Watts DD. Defibrillation by basic emergency medical technicians: effect on survival. Ann Emerg Med 1995; 26:635–639.

    Article  PubMed  CAS  Google Scholar 

  8. White RD, Hankins DG, Bugliosi TF. Seven years’ experience with early defibrillation by police and paramedics in an emergency medical services system. Resuscitation 1998; 39:145–151.

    Article  PubMed  CAS  Google Scholar 

  9. Becker, LB, et al. Outcome of CPR in a large metropolitan area—where are the survivors? Ann Emerg Med 1991; 20:355–361.

    Article  PubMed  CAS  Google Scholar 

  10. Lombardi G, Gallagher J, Gennis P. Outcome of out-of-hospital cardiac arrest in New York City. The Pre-Hospital Arrest Survival Evaluation (PHASE) Study. JAMA 1994; 271:678–683.

    Article  PubMed  CAS  Google Scholar 

  11. Mayfield T. 200 city survey. EMS in the nation’s most-populous cities. JEMS 1998; 23:50–69.

    PubMed  CAS  Google Scholar 

  12. Herlitz J, et al. Rhythm changes during resuscitation from ventricular fibrillation in relation to delay until defibrillation, number of shocks delivered and survival. Resuscitation 1997; 34:17–22.

    Article  PubMed  CAS  Google Scholar 

  13. White RD, Russell JK. Refibrillation, resuscitation and survival in out-of-hospital sudden cardiac arrest victims treated with biphasic automated external defibrillators. Resuscitation 2002; 55:17–23.

    Article  PubMed  Google Scholar 

  14. Gazmuri, RJ. Effects of repetitive electrical shocks on postresuscitation myocardial function. Crit Care Med, 2000 28(Suppl):N228–232.

    Article  PubMed  CAS  Google Scholar 

  15. Weaver WD, et al. Effect of epinephrine and lidocaine therapy on outcome after cardiac arrest due to ventricular fibrillation. Circulation 1990; 82:2027–2034.

    PubMed  CAS  Google Scholar 

  16. Pepe PE, et al. Cardiac arrest presenting with rhythms other than ventricular fibrillation: contribution of resuscitative efforts toward total survivorship. Crit Care Med 1993; 21:1838–1843.

    PubMed  CAS  Google Scholar 

  17. van Walraven C, et al. Do advanced cardiac life support drugs increase resuscitation rates from in-hospital cardiac arrest? The OTAC Study Group. Ann Emerg Med 1998; 32:544–553.

    Article  PubMed  Google Scholar 

  18. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: advanced cardiovascular life support: section 5: pharmacology I: agents for arrhythmias. The American Heart Association in Collaboration with the International Liaison Committee on Resuscitation. Circulation 2000; 102(8 Suppl):I112–I128.

    Google Scholar 

  19. Santini M, Pandozi C, Ricci R. Combining antiarrhythmic drugs and implantable devices therapy: benefits and outcome. J Interv Card Electrophysiol 2000; 4(Suppl):65–68.

    Article  PubMed  Google Scholar 

  20. Manolis AG, et al. Electrical storms in an ICD-recipient with 429 delivered appropriate shocks: therapeutic management with antiarrhythmic drug combination. J Interv Card Electrophysiol 2002; 6:91–94.

    Article  PubMed  Google Scholar 

  21. Curione M, et al. An electrocardiographic criterion to detect AV dissociation in wide QRS tachyarrhythmias. Clin Cardiol 1988; 11:250–252.

    PubMed  CAS  Google Scholar 

  22. Bigger JT, Jr. Digitalis toxicity. J Clin Pharmacology 1985; 25:514–521.

    Article  CAS  Google Scholar 

  23. Hauptman PJ, Kelly RA. Digitalis. Circulation 1999; 99:1265–1270.

    PubMed  CAS  Google Scholar 

  24. Rotem M, et al. Life-threatening Torsade de Pointes arrhythmia associated with head injury. Neurosurgery 1988; 23:89–92.

    Article  PubMed  CAS  Google Scholar 

  25. Roden DM. Torsade de pointes. Clin Cardiol 1993; 16:683–686.

    PubMed  CAS  Google Scholar 

  26. Glassman AH, Bigger JT, Jr. Antipsychotic drugs: prolonged QTc interval, Torsade de pointes, and sudden death. Am J Psychiatry 2001; 158:1774–1782.

    Article  PubMed  CAS  Google Scholar 

  27. Pathak A, et al. Celecoxib-associated Torsade de pointes. Ann Pharmacother 2002; 36:1290, 1291.

    Article  PubMed  Google Scholar 

  28. Cantani A, Mocini V. Antihistamines and the Torsade de point in children with allergic rhinitis. Eur Rev Med Pharmacol Sci 2001; 5:139–142.

    PubMed  CAS  Google Scholar 

  29. Krantz MJ, et al. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med, 2002; 137:501–504.

    PubMed  CAS  Google Scholar 

  30. Kakar A, Byotra SP. Torsade de pointes probably induced by sparfloxacin. J Assoc Physicians India, 2002; 50:1077–1078.

    PubMed  CAS  Google Scholar 

  31. Milberg P, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early after depolarizations and Torsade de pointes. J Pharmacol Exp Ther 2002; 303:218–225.

    Article  PubMed  CAS  Google Scholar 

  32. Farkas A, Lepran I, Papp JG. Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of Torsade de pointes. J Cardiovasc Pharmacol 2002; 39:287–297.

    Article  PubMed  CAS  Google Scholar 

  33. Alter P, Tontsch D, Grimm W. Doxepin-induced Torsade de pointes tachycardia. Ann Intern Med 2001; 135:384–385.

    PubMed  CAS  Google Scholar 

  34. Raehl CL, Patel AK, LeRoy M. Drug-induced torsade de pointes. Clin Pharm 1985; 4:675–690.

    PubMed  CAS  Google Scholar 

  35. Kay GN, et al. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol 1983; 2:806–817.

    PubMed  CAS  Google Scholar 

  36. Bansal AM, et al. Torsade de pointes: successful acute control by lidocaine and chronic control by tocainide in two patients—one each with acquired long QT and the congenital long QT syndrome. Am Heart J 1986; 112:618–621.

    Article  PubMed  CAS  Google Scholar 

  37. Wellens HJ, Brugada P. Diagnosis of ventricular tachycardia from the 12-lead electrocardiogram. Cardiol Clin 1987; 5:511–525.

    PubMed  CAS  Google Scholar 

  38. Brugada P, et al. A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex. Circulation 1991; 83:1649–1659.

    PubMed  CAS  Google Scholar 

  39. Rinkenberger RL, Naccarelli GV. Evaluation and acute treatment of wide complex tachycardias. Crit Care Clin 1989; 5:599–641.

    PubMed  CAS  Google Scholar 

  40. Sager PT, Bhandari AK. Wide complex tachycardias. Differential diagnosis and management. Cardiol Clin 1991; 9:595–618.

    PubMed  CAS  Google Scholar 

  41. Olshansky B. Ventricular tachycardia masquerading as supraventricular tachycardia: a wolf in sheep’s clothing. J Electrocardiol 1988; 21:377–384.

    Article  PubMed  CAS  Google Scholar 

  42. Naccarelli GV, Wolbrette DL, Luck JC. Proarrhythmia. Med Clin North Am 2001; 85:503–526.

    Article  PubMed  CAS  Google Scholar 

  43. Nestico PF, Morganroth J, Horowitz LN. New antiarrhythmic drugs. Drugs 1988; 35:286–319.

    PubMed  CAS  Google Scholar 

  44. Whalley DW, Wendt DJ, Grant AO. Basic concepts in cellular cardiac electrophysiology: Part I: Ion channels, membrane currents, and the action potential. Pacing Clin Electrophysiol 1995; 18:1556–1574.

    Article  PubMed  CAS  Google Scholar 

  45. Whalley DW, Wendt DJ, Grant AO. Basic concepts in cellular cardiac electrophysiology: Part II: Block of ion channels by antiarrhythmic drugs. Pacing Clin Electrophysiol 1995; 18(Pt 1):1686–1704.

    Article  PubMed  CAS  Google Scholar 

  46. Rosen MR. Consequences of the Sicilian Gambit. Eur Heart J 1995; 16(Suppl):32–36.

    PubMed  Google Scholar 

  47. The’ sicilian Gambit’. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. The Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Euro Heart J 1991; 12:1112–1131.

    Google Scholar 

  48. Chaudhry GM, Haffajee CI. Antiarrhythmic agents and proarrhythmia. Crit Care Med 2000; 28(Suppl): N158–N164.

    Article  PubMed  CAS  Google Scholar 

  49. Hondeghem LM. Selective depression of the ischemic and hypoxic myocardium by lidocaine. Proc West Pharmacol Soc 1975; 18:27–30.

    PubMed  CAS  Google Scholar 

  50. Borer JS, et al. Beneficial effect of lidocaine on ventricular electrical stability and spontaneous ventricular fibrillation during experimental myocardial infarction. Am J Cardiol 1976; 37:860–863.

    Article  PubMed  CAS  Google Scholar 

  51. Spear JF, Moore EN, Gerstenblith G. Effect of lidocaine on the ventricular fibrillation threshold in the dog during acute ischemia and premature ventricular contractions. Circulation 1972; 46:65–73.

    PubMed  CAS  Google Scholar 

  52. Lazzara R, et al. Effects of lidocaine on hypoxic and ischemic cardiac cells. Am J Cardiol 1978; 41: 872–879.

    Article  PubMed  CAS  Google Scholar 

  53. Herlitz J, et al. Lidocaine in out-of-hospital ventricular fibrillation. Does it improve survival? Resuscitation 1997; 33:199–205.

    Article  PubMed  CAS  Google Scholar 

  54. Lie KI, et al. Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. Am J Cardiol 1978; 42:486–488.

    Article  PubMed  CAS  Google Scholar 

  55. MacMahon S, et al. Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA 1988; 260:1910–1916.

    Article  PubMed  CAS  Google Scholar 

  56. Hine LK, et al. Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Arch Intern Med 1989; 149:2694–2698.

    Article  PubMed  CAS  Google Scholar 

  57. Dorian P, et al. Lidocaine causes a reversible, concentration-dependent increase in defibrillation energy requirements. J Am Coll Cardiol 1986; 8:327–332.

    PubMed  CAS  Google Scholar 

  58. Echt DS, et al. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs. Sodium channel block and action potential prolongation. Circulation 1989; 79:1106–1117.

    PubMed  CAS  Google Scholar 

  59. Kerber RE, et al. Effect of lidocaine and bretylium on energy requirements for transthoracic defibrillation: experimental studies. J Am Coll Cardiol 1986; 7:397–405.

    PubMed  CAS  Google Scholar 

  60. Peters RW, et al. Lidocaine-related increase in defibrillation threshold. Anesth Analg 1997; 85:299–300.

    Article  PubMed  CAS  Google Scholar 

  61. Vachiery JL, et al. Bretylium tosylate versus lidocaine in experimental cardiac arrest. Am J Emerg Med 1990; 8:492–495.

    Article  PubMed  CAS  Google Scholar 

  62. Leveque PE. Anti-arrhythmic action of bretylium. Nature 1965; 207:203–204.

    Article  PubMed  CAS  Google Scholar 

  63. Bacaner MB. Quantitiative comparison of bretylium with other antifibrillatory drugs. Am J Cardiol 1968; 21:504–512.

    Article  PubMed  CAS  Google Scholar 

  64. Bacaner M. Bretylium tosylate for suppression of induced ventricular fibrillation. Am J Cardiol 1966; 17:528–534.

    Article  PubMed  CAS  Google Scholar 

  65. Rapeport WG. Clinical pharmacokinetics of bretylium. Clin Pharmacokinet 1985; 10:248–256.

    PubMed  CAS  Google Scholar 

  66. Euler DE, et al. Deleterious effects of bretylium on hemodynamic recovery from ventricular fibrillation. Am Heart J 1986; 112:25–31.

    Article  PubMed  CAS  Google Scholar 

  67. Chandrasekaran S, Steinberg JS. Efficacy of bretylium tosylate for ventricular tachycardia. Am J Cardiol 1999; 83:115–117.

    Article  PubMed  CAS  Google Scholar 

  68. Ornato JP, et al. Future directions for resuscitation research. III. External cardiopulmonary resuscitation advanced life support. Resuscitation 1996; 32:139–158.

    Article  PubMed  CAS  Google Scholar 

  69. Gorgels AP, et al. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia. Am J Cardiol 1996; 78:43–46.

    Article  PubMed  CAS  Google Scholar 

  70. Lazzara R. Antiarrhythmic drugs and Torsade de pointes. Eur Heart J 1993; 14(Suppl):88–92.

    PubMed  Google Scholar 

  71. Stewart CE. Amiodarone for ACLS: a critical evaluation. Emerg Med Serv 2001; 30:61–67.

    PubMed  CAS  Google Scholar 

  72. Kudenchuk PJ, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. NEJM 1999; 341:871–878.

    Article  PubMed  CAS  Google Scholar 

  73. Dorian P, Philippon F. The management of acute ventricular tachycardia or fibrillation. Can J Cardiol 2000; 16(Suppl C):16C–19C.

    PubMed  Google Scholar 

  74. Boriani G, et al. High defibrillation threshold at cardioverter defibrillator implantation under amiodarone treatment: favorable effects of D,L-sotalol. Heart & Lung 2000; 29:412–416.

    Article  CAS  Google Scholar 

  75. Kuhlkamp V, et al. Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment. Int J Cardiol 1999; 69: 271–279.

    Article  PubMed  CAS  Google Scholar 

  76. Anastasiou-Nana MI, et al. Amiodarone concentration in human myocardium after rapid intravenous administration. Cardiovasc Drugs Ther 1999; 13:265–270.

    Article  PubMed  CAS  Google Scholar 

  77. Somberg JC, et al. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. Am J Cardiol 2002; 90:853–859.

    Article  PubMed  CAS  Google Scholar 

  78. Tomcsanyi J, et al. Early proarrhythmia during intravenous amiodarone treatment. Pacing Clin Electrophysiol 1999; 22(Pt 1):968–970.

    Article  PubMed  CAS  Google Scholar 

  79. van Opstal JM, et al. Chronic amiodarone evokes no Torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation 2001; 104:2722–2727.

    Article  PubMed  Google Scholar 

  80. Wiesfeld AC, et al. Beta adrenergic blockade in the treatment of sustained ventricular tachycardia or ventricular fibrillation. Pacing Clin Electrophysiol 1996; 19:1026–1035.

    Article  PubMed  CAS  Google Scholar 

  81. Andresen D, et al. Beta blockers: evidence versus wishful thinking. Am J Cardiol 1999; 83:64D–67D.

    Article  PubMed  CAS  Google Scholar 

  82. Reiter MJ, Reiffel JA. Importance of beta blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol 1998; 82:9I–19I.

    Article  PubMed  CAS  Google Scholar 

  83. Anonymous. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. NEJM 1981; 304:801–807.

    Google Scholar 

  84. Hjalmarson A, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 1981; 2:823–827.

    Article  PubMed  CAS  Google Scholar 

  85. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction NEJM 1998; 339: 489–497.

    Article  PubMed  CAS  Google Scholar 

  86. Perez-Castellano N, et al. Benefit of pacing and beta-blockers in idiopathic repetitive polymorphic ventricular tachycardia. J Cardiovasc Electrophysiol 2001; 12:1304–1307.

    Article  PubMed  CAS  Google Scholar 

  87. Fisher JD. A patient with polymorphic ventricular tachycardia controlled by beta-blockers and atrial pacing. J Cardiovasc Electrophysiol 2002; 13:202.

    Article  PubMed  Google Scholar 

  88. Kurose M, et al. Successful treatment of life-threatening ventricular tachycardia with high-dose propranolol under extracorporeal life support and intraaortic balloon pumping. Jpn Circ J 1993; 57:1106–1110.

    PubMed  CAS  Google Scholar 

  89. Bashir Y, et al. A prospective study of the efficacy and safety of adjuvant metoprolol and xamoterol in combination with amiodarone for resistant ventricular tachycardia associated with impaired left ventricular function. Am Heart J 1992; 124:1233–1240.

    Article  PubMed  CAS  Google Scholar 

  90. Ogunyankin KO, Singh BN. Mortality reduction by antiadrenergic modulation of arrhythmogenic substrate: significance of combining beta blockers and amiodarone. Am J Cardiol 1999; 84:76R–82R.

    Article  PubMed  CAS  Google Scholar 

  91. Olson DW, et al. A randomized comparison study of bretylium tosylate and lidocaine in resuscitation of patients from out-of-hospital ventricular fibrillation in a paramedic system. Ann Emerg Med 1984; 13(Pt 2):807–810.

    Article  PubMed  CAS  Google Scholar 

  92. Armengol RE, et al. Lack of effectiveness of lidocaine for sustained, wide QRS complex tachycardia. Ann Emerg Med 1989; 18:254–257.

    Article  PubMed  CAS  Google Scholar 

  93. Nasir N Jr., et al. Evaluation of intravenous lidocaine for the termination of sustained monomorphic ventricular tachycardia in patients with coronary artery disease with or without healed myocardial infarction. Am J Cardiol 1994; 74:1183–1186.

    Article  PubMed  Google Scholar 

  94. Ho DS, et al. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet 1994; 344:18–23.

    Article  PubMed  CAS  Google Scholar 

  95. Mostow ND, et al. Amiodarone: intravenous loading for rapid suppression of complex ventricular arrhythmias. J Am Coll Cardiol 1984; 4:97–104.

    PubMed  CAS  Google Scholar 

  96. Morady F, et al. Intravenous amiodarone in the acute treatment of recurrent symptomatic ventricular tachycardia. Am J Cardiol 1983; 51:156–159.

    Article  PubMed  CAS  Google Scholar 

  97. Helmy I, et al. Use of intravenous amiodarone for emergency treatment of life-threatening ventricular arrhythmias. J Am Coll Cardiol 1988; 12:1015–1022.

    PubMed  CAS  Google Scholar 

  98. Klein RC, et al. Efficacy of intravenous amiodarone as short-term treatment for refractory ventricular tachycardia. Am Heart J 1988; 115(Pt 1):96–101.

    Article  PubMed  CAS  Google Scholar 

  99. Ochi RP, et al. Intravenous amiodarone for the rapid treatment of life-threatening ventricular arrhythmias in critically ill patients with coronary artery disease. Am J Cardiol 1989; 64:599–603.

    Article  PubMed  CAS  Google Scholar 

  100. Schutzenberger W, et al. Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained ventricular tachycardia and ventricular fibrillation. Br Heart J 1989; 62:367–371.

    Article  PubMed  CAS  Google Scholar 

  101. Mooss AN, et al. Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardia. Am J Cardiol 1990; 65:609–614.

    Article  PubMed  CAS  Google Scholar 

  102. Scheinman MM, et al. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995; 92:3264–3272.

    PubMed  CAS  Google Scholar 

  103. Levine JH, et al. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group. J Am Coll Cardiol 1996; 27:67–75.

    Article  PubMed  CAS  Google Scholar 

  104. Kowey PR, et al. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995; 92:3255–3263.

    PubMed  CAS  Google Scholar 

  105. Dorian P, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. NEJM 2002; 346:884–890.

    Article  PubMed  CAS  Google Scholar 

  106. Miller B, et al. Pilot study of intravenous magnesium sulfate in refractory cardiac arrest: safety data and recommendations for future studies. Resuscitation 1995; 30:3–14.

    Article  PubMed  CAS  Google Scholar 

  107. Roffe C, Fletcher S, Woods KL. Investigation of the effects of intravenous magnesium sulphate on cardiac rhythm in acute myocardial infarction. Br Heart J 1994; 71:141–145.

    Article  PubMed  CAS  Google Scholar 

  108. Allegra J, et al. Magnesium sulfate in the treatment of refractory ventricular fibrillation in the prehospital setting. Resuscitation 2001; 49:245–249.

    Article  PubMed  CAS  Google Scholar 

  109. Hassan TB, Jagger C, Barnett DB. A randomised trial to investigate the efficacy of magnesium sulphate for refractory ventricular fibrillation. Emerg Med J 2002; 19:57–62.

    Article  PubMed  CAS  Google Scholar 

  110. Woods KL, Fletcher S. Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1994; 343:816–819.

    Article  PubMed  CAS  Google Scholar 

  111. Iseri LT, Allen BJ, Brodsky MA. Magnesium therapy of cardiac arrhythmias in critical-care medicine. Magnesium 1989; 8:299–306.

    PubMed  CAS  Google Scholar 

  112. Thel MC, et al. Randomised trial of magnesium in in-hospital cardiac arrest. Duke Internal Medicine Housestaff. Lancet 1997; 350:1272–1276.

    Article  PubMed  CAS  Google Scholar 

  113. Tzivoni D, et al. Treatment of Torsade de pointes with magnesium sulfate. Circulation 1988; 77: 392–297.

    PubMed  CAS  Google Scholar 

  114. Geannopoulos CJ, Wilber DJ, Olshansky B. Control of refractory ventricular tachycardia with biventricular assist devices. Pacing Clin Electrophysiol 1991; 14:1432–1434.

    Article  PubMed  CAS  Google Scholar 

  115. Kiseleva I, et al. Mechanoelectric feedback after left ventricular infarction in rats. Cardiovasc Res 2000; 45:370–378.

    Article  PubMed  CAS  Google Scholar 

  116. Movsowitz C, Marchlinski FE. Interactions between implantable cardioverter-defibrillators and class III agents. Am J Cardiol 1998; 82:41I–48I.

    Article  PubMed  CAS  Google Scholar 

  117. Babbs CF, et al. Elevation of ventricular defibrillation threshold in dogs by antiarrhythmic drugs. Am Heart J 1979; 98:345–350.

    Article  PubMed  CAS  Google Scholar 

  118. Chow MS, et al. The effect of lidocaine and bretylium on the defibrillation threshold during cardiac arrest and cardiopulmonary resuscitation. Proc Soc Exp Biol Med 1986; 182:63–67.

    PubMed  CAS  Google Scholar 

  119. Nemec J, Shen WK. Congenital long QT syndromes and Brugada syndrome: the arrhythmogenic ion channel disorders. Expert Opin Pharmacother 2001; 2:773–797.

    Article  PubMed  CAS  Google Scholar 

  120. Naccarelli GV, Antzelevitch C. The Brugada syndrome: clinical, genetic, cellular, and molecular abnormalities. Am J Med 2001; 110:573–581.

    Article  PubMed  CAS  Google Scholar 

  121. Brugada J, Brugada P, Brugada R. The syndrome of right bundle branch block ST segment elevation in V1 to V3 and sudden death—the Brugada syndrome. Europace 1999; 1:156–166.

    Article  PubMed  CAS  Google Scholar 

  122. Chen SM, et al. Brugada syndrome without mutation of the cardiac sodium channel gene in a Taiwanese patient. J Formos Med Asso 2000; 99:860–862.

    CAS  Google Scholar 

  123. Priori SG, et al. Task force on sudden cardiac death of the European Society of Cardiology. Eur Heart J 2001; 22:1374–1450.

    Article  PubMed  CAS  Google Scholar 

  124. Priori SG, et al. Mutations in the Cardiac Ryanodine Receptor Gene (hRyR2) Underlie Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation 2001; 103:196–200.

    PubMed  CAS  Google Scholar 

  125. George CH, et al. In situ modulation of the human cardiac ryanodine receptor (hRyR2) by FKBP12.6. Biochem J 2003; 370(Pt. 2):579–589.

    Article  PubMed  CAS  Google Scholar 

  126. Witchel HJ, Hancox JC. Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current. Clin Exp Pharmacol Physiol 2000; 27:753–766.

    Article  PubMed  CAS  Google Scholar 

  127. Brady WJ, DeBehnke DJ, Laundrie D. Prevalence, therapeutic response, and outcome of ventricular tachycardia in the out-of-hospital setting: a comparison of monomorphic ventricular tachycardia, polymorphic ventricular tachycardia, and Torsades de pointes. Acad Emerg Med 1999; 6:609–617.

    PubMed  CAS  Google Scholar 

  128. Roden DM. A practical approach to Torsade de pointes. Clin Cardiol 1997; 20:131.

    Article  Google Scholar 

  129. Kuo CS, et al. Mechanism of ventricular arrhythmias caused by increased dispersion of repolarization. Eur Heart J 1985:6(Suppl):63–70.

    PubMed  Google Scholar 

  130. Bjornstad H, Tande PM, Refsum H. Cardiac electrophysiology during hypothermia. Implications for medical treatment. Arctic Med Res 1991; 50(Suppl):71–75.

    PubMed  Google Scholar 

  131. Kalla H, Yan GX, Marinchak R. Ventricular fibrillation in a patient with prominent J (Osborn) waves and ST segment elevation in the inferior electrocardiographic leads: a Brugada syndrome variant? J Cardiovasc Electrophysiol 2000; 11:95–98.

    Article  PubMed  CAS  Google Scholar 

  132. Farstad M. et al. Rewarming from accidental hypothermia by extracorporeal circulation. A retrospective study. Eur J Cardiothorac Surg 2001; 20:58–64.

    Article  PubMed  CAS  Google Scholar 

  133. Antunes E, et al. The differential diagnosis of a regular tachycardia with a wide QRS complex on the 12-lead ECG: ventricular tachycardia, supraventricular tachycardia with aberrant intraventricular conduction, and supraventricular tachycardia with anterograde conduction over an accessory pathway. Pacing Clin Electrophysiol 1994; 17:1515–1524.

    Article  PubMed  CAS  Google Scholar 

  134. Elrifai AM, et al. Rewarming, ultraprofound hypothermia and cardiopulmonary bypass. J Extra Corpor Technol 1993; 24:107–112.

    PubMed  CAS  Google Scholar 

  135. Gregory JS, et al. Comparison of three methods of rewarming from hypothermia: advantages of extracorporeal blood warming. J Trauma 1991; 31:1247–1251; discussion 1251, 1252.

    Article  PubMed  CAS  Google Scholar 

  136. Brunette DD, McVaney K. Hypothermic cardiac arrest: an 11 year review of ED management and outcome. Am J Emerg Med 2000; 18:418–422.

    Article  PubMed  CAS  Google Scholar 

  137. Karch SB. Cardiac arrest in cocaine users. Am J Emerg Med 1996; 14:79–81.

    Article  PubMed  CAS  Google Scholar 

  138. Nademanee K, et al. Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation 2000; 102:742–747.

    PubMed  CAS  Google Scholar 

  139. Credner SC, et al. Electrical storm in patients with transvenous implantable cardioverter-defibrillators: incidence, management and prognostic implications. J Am Coll Cardiol 1998; 32:1909–1915.

    Article  PubMed  CAS  Google Scholar 

  140. Telfer EA, et al. Implantable defibrillator use for de novo ventricular tachyarrhythmias encountered after cardiac surgery. Pacing Clin Electrophysiol 2002; 25:951–956.

    Article  PubMed  Google Scholar 

  141. Gregoratos G, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). J Cardiovasc Electrophysiol 2002; 13: 1183–1199.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiac Electrophysiology, University of Iowa Hospitals, Iowa City, IA

    Brian Olshansky MD

  2. Division of Cardiology, University of Iowa Hospitals, Iowa City, IA

    Pamela Nerheim MD

  3. Cardiology Division, University of Iowa College of Medicine, Iowa City, IA

    Richard E. Kerber MD

  4. Department of Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA

    Richard E. Kerber MD

Authors
  1. Brian Olshansky MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pamela Nerheim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard E. Kerber MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Emergency Medicine, Virginia Commonwealth University Health System, Richmond, VA

    Joseph P. Ornato MD, FACP, FACC, FACEP  & Mary Ann Peberdy MD, FACC  & 

  2. Department of Internal Medicine (Cardiology), Virginia Commonwealth University Health System, Richmond, VA

    Joseph P. Ornato MD, FACP, FACC, FACEP  & Mary Ann Peberdy MD, FACC  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Olshansky, B., Nerheim, P., Kerber, R.E. (2005). Anti-Arrhythmic Drugs and Cardiac Resuscitation. In: Ornato, J.P., Peberdy, M.A. (eds) Cardiopulmonary Resuscitation. Contemporary Cardiology. Humana Press. https://doi.org/10.1385/1-59259-814-5:351

Download citation

  • DOI: https://doi.org/10.1385/1-59259-814-5:351

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-283-4

  • Online ISBN: 978-1-59259-814-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation